Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Güllü DavarciMolecular Imaging and Radiochemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, 68167 Mannheim, Germany.
Carmen WänglerResearch Campus M2OLIE, Medical Faculty Mannheim of Heidelberg University, 68167 Mannheim, Germany.ORCID 0000-0003-1161-8669
Klaus EberhardtForschungsreaktor TRIGA Mainz, Johannes-Gutenberg-Universität Mainz, 55128 Mainz, Germany.
Margaret TulessinInstitute of Pathology, School of Medicine and Health, Technical University of Munich (TUM), 81675 Munich, Germany.ORCID 0009-0009-3854-5288
Christopher GeppertForschungsreaktor TRIGA Mainz, Johannes-Gutenberg-Universität Mainz, 55128 Mainz, Germany.
Ralf SchirrmacherDivision of Oncological Imaging, Department of Oncology, University of Alberta, Edmonton, AB T6G 2R3, Canada.ORCID 0000-0002-7098-3036
Gert FrickerInstitute of Pharmacy and Molecular Biotechnology, Heidelberg University, 69120 Heidelberg, Germany.ORCID 0000-0003-3894-961X
Carolin MoglerInstitute of Pathology, School of Medicine and Health, Technical University of Munich (TUM), 81675 Munich, Germany.ORCID 0000-0003-3400-7254
Marc PretzeDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany.ORCID 0000-0002-6432-5694
Björn WänglerMolecular Imaging and Radiochemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, 68167 Mannheim, Germany.ORCID 0000-0003-3877-5576
Funding
German Federal Ministry of Research, Technology and Space (BMFTR) within the Framework "Research Campus - public-private partnership for Innovation" 13GW0747A
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Preclinical Evaluation of Stable Integrin α · full record | OpenQuestion